Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 100

Sort by

Sort Order Select

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Gerben Duns, PhD, Elena Viganò, PhD, Daisuke Ennishi, MD PhD, Clementine Sarkozy, MD, Stacy Hung, Elizabeth Chavez, Katsuyoshi Takata, MD PhD, Anja Mottok, MD PhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 922.

https://doi.org/10.1182/blood-2019-131450

Published: 2019

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

https://doi.org/10.1182/blood-2019-123163

Published: 2019

Journal Articles

Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A U.S. Real-World Observational Study

Xiaoqin Yang, François Laliberté, Guillaume Germain, MSc, Monika Raut, Mei Sheng Duh, Shuvayu S Sen, Dominique Lejeune, Kaushal D Desai, Philippe Armand

Blood (2019) 134 (Supplement_1): 2133.

https://doi.org/10.1182/blood-2019-128368

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

N. Nora Bennani, MD, Grzegorz Nowakowski, MD, Lisa M. Rimsza, MD, Alex A Adjei, MD PhD, Laurence Doyle, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 4090.

https://doi.org/10.1182/blood-2019-129104

Published: 2019

Journal Articles

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Qian Mei, PhD, Wenying Zhang, MD, Yang Liu, MD, Qingming Yang, MD, John E.J. Rasko, MBBS, PhD, Weidong Han, PhD MD

Blood (2019) 134 (Supplement_1): 4072.

https://doi.org/10.1182/blood-2019-121768

Published: 2019

Journal Articles

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Susanne Bram Ednersson, MD, Mimmie Stern, MD, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, MD PhD, Herman Nilsson-Ehle, MD PhD, Sverker Hasselblom, Per-Ola Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3967.

https://doi.org/10.1182/blood-2019-126387

Published: 2019

Journal Articles

Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma

David G. Maloney, MD PhD, Fei Fei Liu, Lisette Nientker, Cathelijne Alleman, Brian Hutton, PhD, Jacob Garcia, MD

Blood (2019) 134 (Supplement_1): 5821.

https://doi.org/10.1182/blood-2019-127664

Published: 2019

Journal Articles

High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hajime Senjo, MD, Kenji Hirata, MD PhD, Koh Izumiyama, MD PhD, Koichiro Minauchi, MD, Kazuo Itoh, Eriko Tsukamoto, Akio Mori, Shuichi Ota, Daigo Hashimoto, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 488.

https://doi.org/10.1182/blood-2019-124390

Published: 2019

Journal Articles

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Blood (2019) 134 (Supplement_1): 1493.

https://doi.org/10.1182/blood-2019-131904

Published: 2019

Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 1584.

https://doi.org/10.1182/blood-2019-123949

Published: 2019

Journal Articles

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Philippe Armand, Pier Luigi Luigi Zinzani, MD, John Palcza, Jane Anne Healy, Akash Nahar, Patricia Marinello, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1548.

https://doi.org/10.1182/blood-2019-127474

Published: 2019

Journal Articles

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

Blood (2019) 134 (10): 802–813.

https://doi.org/10.1182/blood.2019001126

Published: 2019

Includes: Supplemental data

Journal Articles

Bone Marrow Biopsy Is Still Indispensable for Evaluating Bone Marrow Involvement in DLBCL Patients Even in the PET/CT Era

Yusuke Saiki, Naoto Tomita, Akiko Uchida, Satoshi Yokoi, Yuji Nishio, Yoshinori Suzuki, Yasushi Isobe, MD, PhD, Hirotaka Sakai, Masayuki Kato, Masahiro Hoshikawa, Tsuyoshi Kawano, Naoya Nakamura, Ikuo Miura

Blood (2018) 132 (Supplement 1): 5403.

https://doi.org/10.1182/blood-2018-99-113729

Published: 2018

Journal Articles

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Blood (2018) 132 (Supplement 1): 228.

https://doi.org/10.1182/blood-2018-99-110220

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Sirin Khajavian, MD, Matthew Lewis Chase, Justin Darrah, MD, David G. Maloney, MD PhD, Vincent T. Ho, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Stephen J Forman, Auayporn P. Nademanee, MDBS, Yi-Bin Chen, MD, Philippe Armand, MD PhD, Mazyar Shadman, MD MPH

Blood (2018) 132 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2018-99-114155

Published: 2018

Journal Articles

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

Blood (2018) 132 (Supplement 1): 91.

https://doi.org/10.1182/blood-2018-99-114152

Published: 2018

Journal Articles

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens

Blood (2018) 132 (22): 2401–2405.

https://doi.org/10.1182/blood-2018-05-851154

Published: 2018

Includes: Supplemental data

NARROW

Mutational landscape of gray zone lymphoma

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A U.S. Real-World Observational Study

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma

High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

Bone Marrow Biopsy Is Still Indispensable for Evaluating Bone Marrow Involvement in DLBCL Patients Even in the PET/CT Era

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only